Schrodinger, Inc. (SDGR)


Stock Price Forecast

April 23, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Schrodinger, Inc. chart...

About the Company

We do not have any company description for Schrodinger, Inc. at the moment.

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

450

Exchange

Nasdaq

$216M

Total Revenue

450

Employees

$2B

Market Capitalization

73.31

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SDGR News

Schrodinger, Inc.

2mon ago, source: CNN

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The ...

Schrödinger (NASDAQ: SDGR)

1d ago, source: The Motley Fool

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The ...

Schrodinger Inc Ordinary Shares

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Schrödinger, Inc. (SDGR)

7d ago, source: Yahoo Finance

Operator: Welcome to Schrödinger’s Conference Call to review […] While the top- and bottom-line numbers for Schrodinger, Inc. (SDGR) give a sense of how the business performed in the quarter ...

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

6d ago, source:

Schrödinger today reported that on April 15, 2024, the company granted (i) non-statutory stock options and (ii) restricted ...

Schrodinger and Takeda scientists discover new 3CLpro inhibitors

14d ago, source: BioWorld

Researchers at Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have described 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute ...

Schrödinger Highlights Discovery of SGR-1505, Clinical-Stage MALT1 Inhibitor, at American Chemical Society National Meeting

1mon ago, source: Stockhouse

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 ...

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

6d ago, source: Stockhouse

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on April 15, 2024, the company ...

Schrodinger Inc.

24d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...